Management Reaffirms Full-Year 2023 Revenue Growth of at least 25% over Prior Year
Biofrontera Inc. (Nasdaq:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the commercialization of dermatologic products, today announced preliminary unaudited revenues for the three months ended June 30, 2023.
Revenues for the second quarter of 2023 are anticipated to be in the range of approximately $5.7 million to $5.9 million, an increase of approximately 26% to 31% compared with the second quarter of 2022. As a result, revenues for the first half of 2023 are anticipated to be in the range of approximately $14.4 million to $14.6 million, representing growth of approximately 1% to 3% compared with the first half of 2022.
https://finance.yahoo.com/news/biofrontera-inc-announces-preliminary-second-130000893.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.